ストックスクリーナーアプリを入手
1.06
1.85%
-0.02
アフターアワーズ：
1.07
0.01
+0.94%
前日終値:
$1.08
開ける：
$1.08
24時間の取引高:
277.23K
Relative Volume:
0.62
時価総額：
$118.38M
収益：
-
当期純損益:
$-21.65M
株価収益率:
-3.1918
EPS:
-0.3321
ネットキャッシュフロー:
$-15.84M
1週間 パフォーマンス:
+4.95%
1か月 パフォーマンス:
+6.29%
6か月 パフォーマンス:
+2.91%
1年 パフォーマンス:
-19.70%
1日の値動き範囲:
$1.04
$1.08
1週間の範囲:
$0.9492
$1.10
52週間の値動き範囲:
$0.7709
$1.59
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.06 | 120.61M | 0 | -21.65M | -15.84M | -0.3321 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-26 | 開始されました | ROTH MKM | Buy |
| 2024-04-22 | 開始されました | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc (CRDL) 最新ニュース
Fundamentals Check: Can Cardiol Therapeutics Inc maintain its current growth rateJobs Report & Expert Approved Momentum Ideas - baoquankhu1.vn
Can Cardiol Therapeutics Inc generate free cash flow2025 Price Action Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
CRDL Stock Rating Reiterated at 'Buy' by HC Wainwright & Co. | C - GuruFocus
Cardiol Therapeutics (NASDAQ:CRDL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics publishes phase II myocarditis study results - Investing.com
Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure - TipRanks
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure - Investing News Network
Cardiol Therapeutics publishes phase II myocarditis study results By Investing.com - Investing.com India
Myocarditis trial finds CardiolRx reduced heart swelling marker - Stock Titan
How the (CRDL) price action is used to our Advantage (CRDL:CA) - Stock Traders Daily
Equities Analysts Set Expectations for CRDL FY2025 Earnings - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Stock Rating Upgraded by Brookline Cap M - MarketBeat
Analysts Offer Predictions for CRDL FY2025 Earnings - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell? - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1%Time to Sell? - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Upgraded at Brookline Capital Management - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at Brookline Capital Management - MarketBeat
(CRDL) Market Dynamics and Trading Signals (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics files underwriting agreement and warrant indenture By Investing.com - Investing.com Nigeria
Cardiol Therapeutics files underwriting agreement and warrant indenture - Investing.com
Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing - TipRanks
Targets Report: Can Cardiol Therapeutics Inc weather a recessionPortfolio Profit Report & Daily Growth Stock Tips - baoquankhu1.vn
Fund Flows: Will Ambarella Inc stock benefit from M A2025 Trading Volume Trends & Safe Swing Trade Setups - baoquankhu1.vn
Aug Retail: Is MPWR in a bullish channel2025 Volatility Report & Daily Entry Point Trade Alerts - baoquankhu1.vn
(CRDL) Strategic Equity Report (CRDL:CA) - Stock Traders Daily
Can Cardiol Therapeutics Inc. weather a recessionJuly 2025 Analyst Calls & Verified Technical Trade Signals - mfd.ru
Cardiol Therapeutics Secures U.S. Patent for Heart Drugs - MSN
Cardiol Therapeutics Secures $13.5 Million Bought-Deal Financing to Advance Heart Disease Programs - TipRanks
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Investing News Network
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Investing News Network
When the Price of (CRDL) Talks, People Listen (CRDL:CA) - Stock Traders Daily
Heart disease biotech Cardiol raises $14.85M for trials - stocktitan.net
Cardiol Therapeutics Inc. announced that it has received CAD 13.500001 million in funding - marketscreener.com
(CRDL) Equity Trading Insights (CRDL:CA) - Stock Traders Daily
Top Canadian Stocks to Buy Right Away With $5,000 - Yahoo! Finance Canada
Cardiol Therapeutics announces $13.5M bought-deal private placement - MSN
Will Cardiol Therapeutics Inc. (CT9) stock gain from lower interest ratesChart Pattern Recognition & Free Discover Fast Growing Stocks - bollywoodhelpline.com
Why Cardiol Therapeutics Inc. stock is favored by top institutionsCup and Handle Formations & Identify Breakout Stocks - bollywoodhelpline.com
Portfolio Shifts: Will Cardiol Therapeutics Inc outperform tech stocksTake Profit & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Cardiol Therapeutics announces $13.5 million private placement By Investing.com - Investing.com Nigeria
(CRDL) Technical Pivots with Risk Controls (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics announces $13.5 million bought deal financing By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Inc. announced that it expects to receive CAD 13.500001 million in funding - marketscreener.com
Cardiol Therapeutics Secures $13.5 Million Bought Deal Financing to Advance Heart Disease Programs - TipRanks
Cardiol Therapeutics announces $13.5 million private placement - Investing.com
Cardiol Therapeutics announces $13.5 million bought deal financing - Investing.com
Heart drug developer Cardiol lines up $13.5M to fund trials and research - Stock Titan
AI Stocks: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergenceJuly 2025 Fed Impact & AI Enhanced Trading Signals - baoquankhu1.vn
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.5% – Still a Buy? - Defense World
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.5%Still a Buy? - MarketBeat
Cardiol Therapeutics Inc (CRDL) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
0.15%
大文字化:
|
ボリューム (24 時間):